Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000445976
Ethics application status
Not yet submitted
Date submitted
21/04/2011
Date registered
2/05/2011
Date last updated
2/05/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
Effect of transcutaneous electrical nerve stimulation for treating patients with refractory overactive bladder syndrome
Query!
Scientific title
Effect of transcutaneous electrical nerve stimulation for treating patients with refractory overactive bladder syndrome evaluated by bladder diary and patient satisfaction assessment
Query!
Secondary ID [1]
260050
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Overactive bladder syndrome
265712
0
Query!
Condition category
Condition code
Renal and Urogenital
265852
265852
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Transcutaneous electrical nerve stimulation (TENS) for treating patients with refractory overactive bladder syndrome is performed with an Elpha 4 Conti stimulation device applying vaginal electrodes in women and circular penile electrodes in men, the treatment period is 12 weeks stimulating for 20 minutes twice a day (once in the morning, once in the evening).
Query!
Intervention code [1]
264468
0
Treatment: Devices
Query!
Comparator / control treatment
None
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
266614
0
bladder diary (number of voids per 24 hours, voided volume in mL, number of pads used per 24 hours)
Query!
Assessment method [1]
266614
0
Query!
Timepoint [1]
266614
0
before treatment, after 12 weeks of TENS treatment, at 1 year after TENS treatment or if not available at the date of the last known follow-up after TENS treatment
Query!
Primary outcome [2]
266615
0
patient satisfaction assessment (using a questionnaire with a 5 point Likert scale)
Query!
Assessment method [2]
266615
0
Query!
Timepoint [2]
266615
0
before treatment, after 12 weeks of TENS treatment, at 1 year after TENS treatment or if not available at the date of the last known follow-up after TENS treatment
Query!
Secondary outcome [1]
276098
0
adverse events (i.e. general adverse events assessed by questionnaire and categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events, and especially pain, cutaneous irritation, or infection due to TENS treatment)
Query!
Assessment method [1]
276098
0
Query!
Timepoint [1]
276098
0
before treatment, after 12 weeks of TENS treatment, at 1 year after TENS treatment or if not available at the date of the last known follow-up after TENS treatment
Query!
Eligibility
Key inclusion criteria
OAB with urodynamically proven detrusor overactivity, failed behavioural treatment and pharmacotherapy with at least 2 antimuscarinics for a minimum of 1 month, and no previous surgery for OAB
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
pregancy, age <18 years, not fulfilling inclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/12/2003
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
3420
0
Switzerland
Query!
State/province [1]
3420
0
Bern
Query!
Funding & Sponsors
Funding source category [1]
264944
0
Self funded/Unfunded
Query!
Name [1]
264944
0
Query!
Address [1]
264944
0
Query!
Country [1]
264944
0
Query!
Primary sponsor type
Hospital
Query!
Name
Department of Urology
Query!
Address
Department of Urology
Inselspital
University of Bern
3010 Bern
Query!
Country
Switzerland
Query!
Secondary sponsor category [1]
264041
0
None
Query!
Name [1]
264041
0
Query!
Address [1]
264041
0
Query!
Country [1]
264041
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
266903
0
Query!
Ethics committee address [1]
266903
0
Query!
Ethics committee country [1]
266903
0
Query!
Date submitted for ethics approval [1]
266903
0
01/12/2003
Query!
Approval date [1]
266903
0
Query!
Ethics approval number [1]
266903
0
This study has not been judged by an official ethics committee, which has a HREC Number. At this time, the study was discussed, ethically judged, and eventually approved by the staff of the Department of Urology, University of Bern. The study has been conducted according to the Declaration of Helsinki.
Query!
Summary
Brief summary
Overactive bladder syndrome (OAB) is highly prevalent and affects the lives of millions of people worldwide. Although antimuscarinics are the pharmacological treatment of choice for OAB, the effectiveness is limited. Thus, there is an urgent need for effective, well-tolerated therapeutic alternatives. Transcutaneous electrical nerve stimulation (TENS) is an established treatment for OAB in children and may also be a valuable option in adults. We therefore aimed to investigate the effect of TENS for treating adult patients with refractory OAB.
Query!
Trial website
None
Query!
Trial related presentations / publications
None
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32528
0
Query!
Address
32528
0
Query!
Country
32528
0
Query!
Phone
32528
0
Query!
Fax
32528
0
Query!
Email
32528
0
Query!
Contact person for public queries
Name
15775
0
Thomas M. Kessler
Query!
Address
15775
0
Department of Urology
Inselspital
University of Bern
3010 Bern
Query!
Country
15775
0
Switzerland
Query!
Phone
15775
0
+41 31 632 20 45
Query!
Fax
15775
0
Query!
Email
15775
0
[email protected]
Query!
Contact person for scientific queries
Name
6703
0
Thomas M. Kessler
Query!
Address
6703
0
Department of Urology
Inselspital
University of Bern
3010 Bern
Query!
Country
6703
0
Query!
Phone
6703
0
+41 31 632 20 45
Query!
Fax
6703
0
Query!
Email
6703
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF